Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes.
The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Hypoglycaemia is the limiting factor in the glycaemic management of diabetes. Iatrogenic hypoglycaemia is typically the result of the interplay of insulin excess and compromised glucose counterregulation in Type I (insulin-dependent) diabetes mellitus. Insulin concentrations do not decrease and glucagon and epinephrine concentrations do not increase normally as glucose concentrations decrease. The concept of hypoglycaemia-associated autonomic failure (HAAF) in Type I diabetes posits that recent antecedent iatrogenic hypoglycaemia causes both defective glucose counterregulation (by reducing the epinephrine response in the setting of an absent glucagon response) and hypoglycaemia unawareness (by reducing the autonomic and the resulting neurogenic symptom responses). Perhaps the most compelling support for HAAF is the finding that as little as 2 to 3 weeks of scrupulous avoidance of hypoglycaemia reverses hypoglycaemia unawareness and improves the reduced epinephrine component of defective glucose counterregulation in most affected patients. The mediator and mechanism of HAAF are not known but are under active investigation. The glucagon response to hypoglycaemia is also reduced in patients approaching the insulin deficient end of the spectrum of Type II (non-insulin-dependent) diabetes mellitus, and glycaemic thresholds for autonomic (including epinephrine) and symptomatic responses to hypoglycaemia are shifted to lower plasma glucose concentrations after hypoglycaemia in Type II diabetes. Thus, patients with advanced Type II diabetes are also at risk for HAAF. While it is possible to minimise the risk of hypoglycaemia by reducing risks -- including a 2 to 3 week period of scrupulous avoidance of hypoglycaemia in patients with hypoglycaemia unawareness -- methods that provide glucose-regulated insulin replacement or secretion are needed to eliminate hypoglycaemia and maintain euglycaemia over a lifetime of diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Because of steady improvements in the glycemic management of diabetes, it is possible both to improve glycemic control and to minimize the risk of hypoglycemia in many patients (12, 16, 84 -86).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [84]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypoglycemia in diabetes is fundamentally the result of treatments that raise insulin levels and thus lower plasma glucose concentrations (12,16,84,85).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [84]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Those treatments include insulin or insulin secretagogues such as a sulfonylurea or a nonsulfonylurea insulin secretagogue (e.g.nateglinide or repaglinide).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [84]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In type 1 diabetes, deficiency of the secretory response of glucagon to hypoglycemia is an early acquired abnormality of counterregulation.The catecholamine response compensates for several years but declines with time (1).”
From Hypoglycemia in Type 2 Diabetes (2005) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Treatment-induced hypoglycemia is the limiting factor in the glycemic management of diabetes (12,16,84).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [84]
15 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Plum, F. (1960) · Archives of Neurology · doi:10.1001/archneur.1960.03840090124020 · Cited by 10,364
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059 · cited 2×
“Enough insulin, or any effective drug, to lower plasma glucose concentrations to or below the normal range would eliminate the symptoms of hyperglycaemia, prevent the acute hyperglycaemic complications (ketoacidosis, hyperosmolar syndrome), almost assuredly prevent the long-term microvascular complications [1, 2] and…”
BackgroundKhaw, K.-T. (2001) · BMJ · doi:10.1136/bmj.322.7277.15 · Cited by 1,017
Gold, A. E., Macleod, K. M., & Frier, B. M. (1994) · Diabetes Care · doi:10.2337/diacare.17.7.697 · Cited by 810
Gerich, J. E., Langlois, M., Noacco, C., Karam, J. H., & Forsham, P. H. (1973) · Science · doi:10.1126/science.182.4108.171 · Cited by 688 · cited 1×
“Finally, we and others have begun to study the mechanisms of the normal glucagon response to hypoglycaemia with the aim of gaining insight into the mechanism of the absence of the glucagon response in Type I diabetes [22], a critical component of defective glucose counterregulation and HAAF.”
BackgroundMitrakou, A., Ryan, C., Veneman, T., Mokan, M., Jenssen, T., Kiss, I., Durrant, J., Cryer, P., & Gerich, J. (1991) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1991.260.1.e67 · Cited by 558 · cited 2×
“0 mmol/l (54 mg/dl) respectively) are reproducible in healthy subjects [13, 14, 15], they shift to higher plasma glucose concentrations in poorly controlled diabetes [16, 17] and to lower plasma glucose concentrations following episodes of hypoglycaemia [18, 19, 20, 21].”
BackgroundSelf-citationHeller, S. R., & Cryer, P. E. (1991) · Diabetes · doi:10.2337/diab.40.2.223 · Cited by 531
Self-citation&NA; (1994) · Survey of Anesthesiology · doi:10.1097/00132586-199406000-00052 · Cited by 487
Dagogo-Jack, S. E., Craft, S., & Cryer, P. E. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116302 · Cited by 471
Self-citation
Cited by
Items 201–300 of 793
Whaley, J. M., Tirmenstein, M. A., Reilly, Poucher, Saye, Parikh, & List (2012) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s22503 · Cited by 68
“There are challenges in treating T2DM with available therapeutic options.(10) Most current therapies increase insulin levels or enhance insulin action.”
Muñoz, A., Hu, M., Hussain, K., Bryan, J., Aguilar-Bryan, L., & Rajan, A. S. (2005) · Endocrinology · doi:10.1210/en.2005-0637 · Cited by 58
“The stimulation of glucagon release by insulin-induced hypoglycemia during the counterregulatory response is impaired in type 1 diabetes and in advanced stages of type 2 diabetes ( 3 , 4). This reduced secretion predisposesindividualstorepeatedhypoglycemicepisodesthat may lead to coma or neurological injury (5).”
BackgroundGingras, V., RABASA-LHORET, R. P. R., Messier, V., Ladouceur, M., Legault, L., & Haidar, A. (2015) · Diabetes & Metabolism · doi:10.1016/j.diabet.2015.05.001 · Cited by 66
Herrero, P., Georgiou, P., Oliver, N., Reddy, M., Johnston, D., & Toumazou, C. (2013) · Journal of Diabetes Science and Technology · doi:10.1177/193229681300700416 · Cited by 55
“Step 1: The known insulin (glucagon) delivery rates were used to estimate parameters of the insulin (glucagon) absorption model [Equations (13)–(15) and Equations (16)–(18)].”
MethodAssociation of aerobic fitness level with exercise‐induced hypoglycaemia in Type 1 diabetes
Al Khalifah, R. A., Suppère, C., Haidar, A., Rabasa‐Lhoret, R., Ladouceur, M., & Legault, L. (2016) · Diabetic Medicine · doi:10.1111/dme.13070 · Cited by 55
Sorli, C., Warren, M., Oyer, D., Mersebach, H., Johansen, T., & Gough, S. C. L. (2013) · Drugs & Aging · doi:10.1007/s40266-013-0128-2 · Cited by 54
“While insulin is effective for all patients with diabetes, hypoglycaemia and fear of hypoglycaemia associated with insulin have resulted in delays in both initiation and intensification, thus limiting patients’ well-being and their ability to reach glycaemic targets [13].”
BackgroundHuang, Y.-C., Rupnik, M. S., Karimian, N., Herrera, P. L., Gilon, P., Feng, Z.-P., & Gaisano, H. Y. (2013) · Diabetes · doi:10.2337/db11-0786 · Cited by 54
“As diabetes progresses, a cells suffer from “hypoglycemic blindness,” becoming sluggish in response to low glucose, exacerbating life-threatening acute hypoglycemic episodes (3,5).”
Diabetes distress may adversely affect the eating styles of women with type 1 diabetes
Martyn-Nemeth, P., Quinn, L., Hacker, E., Park, H., & Kujath, A. S. (2014) · Acta Diabetologica · doi:10.1007/s00592-014-0575-1 · Cited by 53
“Hypoglycemia is the limiting factor in attaining glycemic control [1].”
Defective Counterregulation and Hypoglycemia Unawareness in Diabetes
Reno, C. M., Litvin, M., Clark, A. L., & Fisher, S. J. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.11.005 · Cited by 53
Solomou, A., Meur, G., Bellomo, E. A., Hodson, D. J., Tomás, A., Migrenne, S., Philippe, E., Herrera, P. L., Magnan, C., & Rutter, G. A. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.645291 · Cited by 60
“By contrast, glucagon secretion is required in type 1 diabetes to ensure an adequate response to insulin-induced hypoglycemia, and a failure of this process contributes significantly to mortality in the latter disease (7).”
BackgroundNew insights into seaweed polyphenols on glucose homeostasis
Murugan, A. C., Karim, M. R., Yusoff, M. M., Tan, S. H., Asras, M. F. F., & Rashid, S. S. (2015) · Pharmaceutical Biology · doi:10.3109/13880209.2014.959615 · Cited by 61
“This hormone is responsible for maintaining the plasma glucose in respective levels when there is additional prerequisite (Cryer, 2002).”
BackgroundHypoglycemia in type 2 diabetes
Banarer, S., & Cryer, P. E. (2004) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.04.003 · Cited by 57
“All three of these mechanisms are impaired in patients with T1DM and may be reduced in advanced T2DM [4,5].”
BackgroundInfluentialSelf-citationA Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination
Neuman, J. C., Truchan, N. A., Joseph, J. W., & Kimple, M. E. (2014) · Journal of Visualized Experiments · doi:10.3791/50374 · Cited by 54
Hypoglycemia in Patients with Type 1 Diabetes: Epidemiology, Pathogenesis, and Prevention
Awoniyi, O., Rehman, R., & Dagogo-Jack, S. E. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0411-y · Cited by 59
Hermanns, N., Kulzer, B., Krichbaum, M., Kubiak, T., & Haak, T. (2010) · Diabetes Care · doi:10.2337/dc09-1656 · Cited by 52
Treating type 1 diabetes: from strategies for insulin delivery to dual hormonal control.
McCall, A. L., & Farhy, L. S. (2013) · PubMed · Cited by 82
Esposito, K., Ciotola, M., Maiorino, M. I., Gualdiero, R., Schisano, B., Ceriello, A., Beneduce, F., Feola, G., & Giugliano, D. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-8-200810210-00005 · Cited by 51
“Tight glycemic control is known to increase the risk for hypoglycemia, representing a major barrier to sustained glycemic control with insulin therapy (35).”
BackgroundSiebenhofer, A., Plank, J., Berghold, A., Horvath, K., Sawicki, P. T., Beck, P., & Pieber, T. R. (2004) · Diabetologia · doi:10.1007/s00125-004-1545-x · Cited by 54
“Furthermore, based on the evidence available on this topic, it does not seem plausible that the frequency of severe hypoglycaemia can be reduced without a concomitant reduction in the frequency of overall hypoglycaemic episodes [63].”
BackgroundIndividualizing Targets and Tactics for High-Risk Patients With Type 2 Diabetes
Riddle, M. C., & Karl, D. M. (2012) · Diabetes Care · doi:10.2337/dc12-0650 · Cited by 51
Borzì, V., Frasson, S., Gussoni, G., Lillo, M., Gerloni, R., Augello, G., Gulli, G., Ceriello, A., Solerte, B., Bonizzoni, E., et al. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.01.020 · Cited by 58
“[25] Cryer PE.”
BackgroundDerijks, H. J., Heerdink, E. R., Koning, F. H. P. D., Janknegt, R., Klungel, O. H., & Egberts, T. C. G. (2008) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1562 · Cited by 52
“Intensive treatment with insulin and/or oral antidiabetic drugs (OADs), however, significantly increases the risk of hypoglycaemia which is the limiting factor in glycaemic management of diabetes.(8) It has been estimated that 2–4% of deaths of patients with type 1 diabetes mellitus are related to hypoglycaemia.”
BackgroundLukashevich, V., Schweizer, A., Foley, J. E., Dickinson, Groop, P., & Kothny, W. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s39300 · Cited by 55
The social burden of hypoglycemia in the elderly
Nicolucci, A., Pintaudi, B., Rossi, M. C., Messina, R., Dotta, F., Frontoni, S., Caputo, S., & Lauro, R. (2015) · Acta Diabetologica · doi:10.1007/s00592-015-0717-0 · Cited by 58
Is There a Place for Insulin Pump Therapy in Your Practice?
Skyler, J. S., Ponder, S., Kruger, D. F., Matheson, D., & Parkin, C. G. (2007) · Clinical Diabetes · doi:10.2337/diaclin.25.2.50 · Cited by 49
Qvisth, V., Toft, E., Enoksson, S., & Bolinder, J. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1313 · Cited by 59
Basal Insulin Use With GLP-1 Receptor Agonists
Anderson, S. L., & Trujillo, J. M. (2016) · Diabetes Spectrum · doi:10.2337/diaspect.29.3.152 · Cited by 58
Little, S. A., Leelarathna, L., Barendse, S. M., Walkinshaw, E., Tan, H. K., Lubina Solomon, A., de Zoysa, N., Rogers, H., Choudhary, P., Amiel, S. A., et al. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2492 · Cited by 48
Hypoglycemia Fear and Self-efficacy of Turkish Patients Receiving Insulin Therapy
Erol, Ö., & Enç, N. (2011) · Asian Nursing Research · doi:10.1016/j.anr.2011.12.001 · Cited by 62
Mathieu, C., Dandona, P., Phillip, M., Oron, T., Lind, M., Hansen, L., Thorén, F., Xu, J., Langkilde, A. M., & on behalf of the DEPICT-1 and DEPICT-2 Investigators (2019) · Diabetes Care · doi:10.2337/dc18-1983 · Cited by 48
Iatrogenic Inpatient Hypoglycemia: Risk Factors, Treatment, and Prevention
Maynard, G. A., Huynh, M. P., & Renvall, M. (2008) · Diabetes Spectrum · doi:10.2337/diaspect.21.4.241 · Cited by 48
Hypoglycaemia: current management and controversies
Choudhary, P., & Amiel, S. A. (2011) · Postgraduate Medical Journal · doi:10.1136/pgmj.2008.068197 · Cited by 47
“Hypoglycaemia (literally low blood glucose concentration) and the fear it engenders is a major barrier to achieving the glycaemic targets known to minimise risk of complications of diabetes.”
BackgroundBrain glycogen supercompensation in the mouse after recovery from insulin‐induced hypoglycemia
Canada, S. E., Weaver, S. A., Sharpe, S. N., & Pederson, B. A. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22579 · Cited by 47
“Hypoglycemia unawareness, a component of HAAF, reportedly persists for 1–2 weeks following a hypoglycemic bout in humans (Cryer, 2002).”
BackgroundFactors Influencing the Effectiveness of Glucagon for Preventing Hypoglycemia
Castle, J. R., Engle, J. M., Youssef, J. E., Massoud, R. G., & Ward, W. K. (2010) · Journal of Diabetes Science and Technology · doi:10.1177/193229681000400603 · Cited by 47
Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus
Siebenhofer, A., Plank, J., Berghold, A., Narath, M., Gfrerer, R., & Pieber, T. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003287.pub3 · Cited by 49
Hypoglycemia in stable, insulin-treated veterans with type 2 diabetes
Murata, G. H., Duckworth, W. C., Shah, J. H., Wendel, C. S., Mohler, M. J., & Hoffman, R. M. (2005) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2004.02.001 · Cited by 57
The Future of Basal Insulin Supplementation
Simon, A. C. R., & DeVries, J. H. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0251 · Cited by 46
“7 An insulin analog with a really flat or near-flat ‘‘peakless’’ time–action profile could limit peak-induced hypoglycemia.”
Regional brain activation during hypoglycemia in type 1 diabetes
Musen, G., Simonson, D. C., Bolo, N. R., Driscoll, A., Weinger, K., Raji, A., Théberge, J., Renshaw, P. F., & Jacobson, A. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2007 · Cited by 33
“The combination of these factors impairs the mechanisms required to restore glucose levels toward normal (7).”
BackgroundHøi-Hansen, T., Pedersen‐Bjergaard, U., & Thorsteinsson, B. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01552.x · Cited by 51
Raju, B., McGregor, V. P., & Cryer, P. E. (2003) · Diabetes · doi:10.2337/diabetes.52.8.2083 · Cited by 46
“The clinical impact of HAAF, including the finding that as little as 2–3 weeks of scrupulous avoidance of hypoglycemia reverses hypoglycemia unawareness and improves the reduced epinephrine component of defective glucose counterregulation in most affected patients is well documented (1,4).”
BackgroundInfluentialSelf-citationControl glucémico en pacientes con diabetes mellitus tipo 2 en España
Pérez, A., Mediavilla, J., Miñambres, I., & Alsina, D. G.-S. (2014) · Revista Clínica Española · doi:10.1016/j.rce.2014.05.028 · Cited by 56
Bradley, C., & Gilbride, C. J. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00871.x · Cited by 50
Kim, A., Knudsen, J. G., Madara, J. C., Benrick, A., Hill, T., Kadir, L. A., Kellard, J. A., Mellander, L., Miranda, C., Lin, H., et al. (2021) · eLife · doi:10.7554/elife.72919 · Cited by 54
Bakatselos, S. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(11)70020-1 · Cited by 55
Regulating Glucagon Secretion: Somatostatin in the Spotlight
Rutter, G. A. (2009) · Diabetes · doi:10.2337/db08-1534 · Cited by 51
“However, failure to secrete adequate quantities of glucagon in response to insulin-induced hypoglycemia characterizes longstanding type 1 diabetes (4) and is an important contributor to mortality in this disease, accounting for 2–4% of all deaths (5).”
BackgroundKoivikko, M. L., Tulppo, M. P., Kiviniemi, A. M., Kallio, M. A., Perkiömäki, J. S., Salmela, P. I., Airaksinen, K. E. J., & Huikuri, H. V. (2012) · Diabetes Care · doi:10.2337/dc11-2120 · Cited by 43
Assessing hyperglycemia avoidance in people with Type 1 diabetes
Singh, H., Gonder-Frederick, L. A., Schmidt, K., Ford, D., Vajda, K., Hawley, J. S., & Cox, D. J. (2014) · Diabetes Management · doi:10.2217/dmt.14.3 · Cited by 51
Siegmund, T., Tentolouris, N., Knudsen, S. T., Lapolla, A., Prager, R., Phan, T., Wolden, M. L., Schultes, B., & for the EU‐TREAT study group (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13149 · Cited by 44
“3) kg/m2, with HbA1c 68 (15) mmol/mol (8.”
Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside
Wu, L., Tsang, V., Sasson, S. C., Menzies, A. M., Carlino, M. S., Brown, D. A., Clifton-Bligh, R. J., & Gunton, J. E. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.764138 · Cited by 48
“This has correlated with findings of reduced glucagon responses in those with established T1D (97, 98), although glucagon responses in early T1D have been mixed (99, 100).”
BackgroundMcCall, A. L., & Kovatchev, B. P. (2009) · Journal of Diabetes Science and Technology · doi:10.1177/193229680900300102 · Cited by 44
Rosenstock, J., Franco, D., Korpachev, V., Shumel, B., Ma, Y., Baughman, R., Amin, N., McGill, J. B., & for the Affinity 2 Study Group (2015) · Diabetes Care · doi:10.2337/dc15-0629 · Cited by 43
Rosenstock, J., Fonseca, V., Schinzel, S., Dain, M.-P., Mullins, P., & Riddle, M. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.04.003 · Cited by 43
“Fear of hypoglycemia is one of the key factors that prevent good glycemic control because patients and healthcare providers are discouraged from starting or intensifying insulin treatment (Cryer, 1999, 2002; Korytkowski, 2002).”
BackgroundPrenatal exposure to bisphenol A alters mouse fetal pancreatic morphology and islet composition
Whitehead, R., Guan, H., Arany, E. J., Cernea, M., & Yang, K. (2016) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2015-0052 · Cited by 47
“As diabetes progresses and becomes more severe, β-cells atrophy and α-cells experience “hypoglycemic blindness”, becoming slow in response to low glucose levels [49, 50].”
BackgroundKenny, C. (2013) · Primary care diabetes · doi:10.1016/j.pcd.2013.09.002 · Cited by 50
“More long-term factors that can influence the risk include change in weight, renal or liver dysfunction and concomitant medications [12,28,29].”
BackgroundGregory, J. M., Kraft, G., Scott, M. F., Neal, D. W., Farmer, B., Smith, M. S., Hastings, J. R., Allen, E. J., Donahue, E. P., Rivera, N., et al. (2015) · Diabetes · doi:10.2337/db15-0071 · Cited by 44
“Previous research has established the importance of aggressive control of hyperglycemia to mitigate microvascular (1-4) and possibly macrovascular (5-9) complications, but a principle limitation of this approach is increased hypoglycemia and its potential for devastating neurologic consequences (6; 10-15).”
Backgroundde Galan, B. E., McCrimmon, R. J., Ibberson, M. R., Heller, S. R., Choudhary, P., Pouwer, F., Speight, J., Carlton, J., Pieber, T. R., Rosilio, M., et al. (2020) · Diabetic Medicine · doi:10.1111/dme.14240 · Cited by 44
Davies, M. J., Sinnassamy, P., Storms, F., & Gomis, R. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.09.013 · Cited by 42
“However, there are barriers to initiating insulin [2, 3], including fear of hypoglycemia, fear of multiple injections, and weight gain.”
BackgroundContinuous Glucose Monitoring: Impact on Hypoglycemia
van Beers, C. A. J., & DeVries, J. H. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816653411 · Cited by 41
“However, in daily practice, hypoglycemia remains the main side effect of insulin therapy and barrier to achieving glycemic targets.(5) The categorization of hypoglycemic episodes is a matter of continuous debate.”
BackgroundHypoglycaemia unawareness in patients with type 1 diabetes
Szadkowska, A., Czyżewska, K., Pietrzak, I., Mianowska, B., Jarosz-Chobot, P. A., & Myśliwiec, M. (2018) · Pediatric Endocrinology Diabetes and Metabolism · doi:10.5114/pedm.2018.80994 · Cited by 46
Yanai, H., Adachi, H., Katsuyama, H., Moriyama, S., Hamasaki, H., & Sako, A. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i1.30 · Cited by 46
Kawaguchi, Y., Sawa, J., Sakuma, N., & Kumeda, Y. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.12884 · Cited by 40
Emotional changes during experimentally induced hypoglycaemia in type 1 diabetes
Hermanns, N., Kubiak, T., Kulzer, B., & Haak, T. (2003) · Biological Psychology · doi:10.1016/s0301-0511(03)00027-9 · Cited by 40
Rosenstock, J., Rood, J. A., Cobitz, A. R., Huang, C., & Garber, A. J. (2006) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00648.x · Cited by 41
Ranjan, A., Schmidt, S., Madsbad, S., Holst, J. J., & Nørgaard, K. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12627 · Cited by 39
“The risk of hypoglycaemia is the main challenge to achieving optimum glycaemic control in patients with type 1 diabetes [1].”
BackgroundEfficacy Determinants of Subcutaneous Microdose Glucagon during Closed-Loop Control
Russell, S. J., El-Khatib, F. H., Nathan, D. M., & Damiano, E. R. (2010) · Journal of Diabetes Science and Technology · doi:10.1177/193229681000400602 · Cited by 42
Haymond, M. W., Redondo, M. J., McKay, S., Cummins, M. J., Newswanger, B., Kinzell, J., & Prestrelski, S. (2016) · Diabetes Care · doi:10.2337/dc15-2124 · Cited by 39
Roadmap to the artificial pancreas
Hovorka, R., Wilinska, M. E., Chassin, L. J., & Dunger, D. B. (2006) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(06)70027-4 · Cited by 39
Giménez, M., Lara, M., & Conget, I. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0028 · Cited by 38
Can a Tool That Automates Insulin Titration Be a Key to Diabetes Management?
Bergenstal, R. M., Bashan, E., McShane, M., Johnson, M., & Hodish, I. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0303 · Cited by 38
“11,12 The process of insulin titration is complex and governed by two contradicting forces: the achievement of near-normal glucose readings and the avoidance of hypoglycemia.”
Hendrieckx, C., Hagger, V., Jenkins, A., Skinner, T. C., Pouwer, F., & Speight, J. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.11.013 · Cited by 38
Laitinen, T. P., Huopio, H., Vauhkonen, I., Camaro, C., Hartikainen, J. E. K., Laakso, M., & NISKANEN, L. K. (2003) · Clinical Science · doi:10.1042/cs20030079 · Cited by 38
Chow, L. S., Zmora, R., Ma, S., Seaquist, E. R., & Schreiner, P. J. (2018) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2018-000527 · Cited by 37
“The lower long-term risk for SH associated with baseline sulfonylurea use was unexpected, although this may actually reflect non-insulin-dependent diabetes, which has more preserved insulin secretion and counter-regulatory response to hypoglycemia than insulin-dependent diabetes.(31) The mechanism associating baseline…”
BackgroundNilsson, M. S. D., Jensen, N. J., Gejl, M., Bergmann, M., Storgaard, H., Zander, M., Miskowiak, K. W., & Rungby, J. (2019) · Diabetologia · doi:10.1007/s00125-019-4964-4 · Cited by 38
Schwartz, S. S., & Kohl, B. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0468 · Cited by 40
Weinberg, M. E., Bacchetti, P., & Rushakoff, R. J. (2010) · Journal of Diabetes Science and Technology · doi:10.1177/193229681000400311 · Cited by 35
“This algorithm would exclude glucose values (1) when the initial glucose result is spurious (e.”
BackgroundMethodJensen, M. H., Christensen, T. F., Tarnow, L., Seto, E., Dencker Johansen, M., & Hejlesen, O. K. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0069 · Cited by 35
“Unfortunately, intensive insulin therapy results in a two- to threefold increase in the prevalence of hypoglycemia—low blood glucose, which in severe cases is potentially fatal and has been associated with ‘‘dead in bed’’ syndrome, in which patients are found dead in their beds.(3) Consequently, patients with hypoglyc…”
Ghandi, K., Pieri, B., Dornhorst, A., & Hussain, S. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00965-0 · Cited by 34
Glycemic control in patients with type 2 diabetes mellitus in Spain
Pérez, A., Mediavilla, J., Miñambres, I., & González-Segura, D. (2014) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2014.05.007 · Cited by 35
Nguyen, H. T., Ghevondian, N., & Jones, T. W. (2008) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/iembs.2008.4649405 · Cited by 38
BAJAJ, H. S., Venn, K., Ye, C., & Aronson, R. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0182 · Cited by 40
Østergaard, H. B., Mandrup-Poulsen, T. R., Berkelmans, G. F. N., van der Graaf, Y., Visseren, F. L. J., & Westerink, J. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.04.006 · Cited by 34
Goldberg, P. A., Weiss, R., McCrimmon, R. J., Hintz, E. V., Dziura, J. D., & Sherwin, R. S. (2006) · Diabetes · doi:10.2337/diabetes.55.04.06.db05-1169 · Cited by 34
Yan, P., Li, L., Yang, M., Liu, D., Liu, H., Boden, G. H., & Yang, G. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.02.030 · Cited by 33
“[3,4].”
Duckworth, W. C., & Davis, S. N. (2007) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2007.01.001 · Cited by 36
“Although many factors can contribute to poor glycemic control in patients with Type 2 diabetes, the frequent failure to achieve treatment goals may be due in part to a widespread reluctance of physicians as well as patients to add insulin to the therapeutic regimen (Cryer, 2002; Hayward, Manning, Kaplan, Wagner, & Gre…”
BackgroundHospitalization and Discharge Education of Emergency Department Patients With Hypoglycemia
Ginde, A. A., Pallin, D. J., & Camargo, C. A. (2008) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721708321022 · Cited by 38
“Mode of arrival Ambulance 298 68 (64-73) 121 41 (35-46) 177 59 (54-65) Walk-in 86 20 (16-24) 32 37 (27-48) 54 63 (52-73) Not documented 52 12 (9-15) 24 46 (32-61) 28 54 (39-68) Prehospital glucose <50 mg/dL 226 52 (47-57) 88 39 (33-46) 138 61 (54-67) 50-69 mg/dL 56 13 (10-16) 20 36 (23-50) 36 64 (50-77) 70-99 mg/dL 17…”
InfluentialOtlivanchik, O., Foll, C. L., & Levin, B. E. (2014) · Diabetes · doi:10.2337/db14-0671 · Cited by 38
“Iatrogenic hypoglycemia is a significant clinical problem in type 1 and type 2 diabetic patients treated with exogenous insulin [1-3].”
BackgroundVloemans, A. F., van Beers, C. A. J., de Wit, M., Cleijne, W., Rondags, S. M. P. A., Geelhoed-Duijvestijn, P. H. L. M., Kramer, M. H. H., Serné, E. H., & Snoek, F. J. (2017) · Diabetic Medicine · doi:10.1111/dme.13429 · Cited by 42
In vivo gene therapy for diabetes mellitus
Chan, L., Fujimiya, M., & Kojima, H. (2003) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2003.08.003 · Cited by 42
Baxter, M. (2008) · Acta Diabetologica · doi:10.1007/s00592-008-0052-9 · Cited by 35
“factors [26, 27].”
Nguyen, H. T., Ghevondian, N., & Jones, T. W. (2006) · Conference proceedings · doi:10.1109/iembs.2006.259482 · Cited by 33
Hypoglycaemia with pioglitazone: analysis of data from the Prescription‐Event Monitoring study
Vlckova, V., Cornelius, V., Kasliwal, R., Wilton, L., & Shakir, S. (2010) · Journal of Evaluation in Clinical Practice · doi:10.1111/j.1365-2753.2009.01280.x · Cited by 32
Kovatchev, B. P. (2012) · Scientifica · doi:10.6064/2012/283821 · Cited by 39
“As a result, hypoglycemia was identi�ed as the primary barrier to optimal diabetes control [49, 50].”
BackgroundClinical Application of Time in Range and Other Metrics
Aleppo, G. (2021) · Diabetes Spectrum · doi:10.2337/ds20-0093 · Cited by 35
Cathepsin L Inhibition Prevents Murine Autoimmune Diabetes via Suppression of CD8+ T Cell Activity
Yamada, A., Ishimaru, N., Arakaki, R., Katunuma, N., & Hayashi, Y. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012894 · Cited by 32
“Although type-1 diabetes can be controlled by insulin injections, individuals who develop the disease may suffer long-term complications that include blindness, kidney failure and premature vascular disease leading to early death [27,28].”
BackgroundBoido, A., Ceriani, V., & Pontiroli, A. E. (2014) · Acta Diabetologica · doi:10.1007/s00592-014-0665-0 · Cited by 34
“However, hypoglycemia is a common side effect of glucose-lowering therapy, and severe hypoglycemia (SH) is a clinically and economically [4] significant complication in patients receiving insulin [1–3], limiting lifetime maintenance of euglycemia in the vast majority of patients [5].”
BackgroundCamacho, R. C., Pencek, R., Lacy, D. B., James, F. D., Donahue, E. P., & Wasserman, D. H. (2005) · Diabetes · doi:10.2337/diabetes.54.2.373 · Cited by 32
“Iatrogenic hypoglycemia is the number one shortterm complication for type 1 (1) and type 2 (2) diabetic patients striving to maintain tight glycemic control.”
BackgroundEarly Insulin: An Important Therapeutic Strategy
DAILEY, G. E. (2005) · Diabetes Care · doi:10.2337/diacare.28.1.220 · Cited by 32
“There seems to be general agreement in the current literature that the risk of severe hypoglycemia is substantially lower in type 2 than in type 1 diabetes, even in those intensively treated with insulin to comparable glycemic targets (5).”
BackgroundEby, E. L., Wang, P., Curtis, B. H., Xie, J., Haldane, D. C., Idris, I., Peters, A. L., Hood, R. C., & Jackson, J. A. (2013) · Journal of Medical Economics · doi:10.3111/13696998.2013.772059 · Cited by 31
Shajith Anoop, S., Misra, A., Bhatt, S. P., Gulati, S., Mahajan, H., & Prabakaran, G. (2017) · Journal of Diabetes Research · doi:10.1155/2017/2376016 · Cited by 32
“In patients with diabetes, the secretory response of α cells to low-glucose concentrations is impaired predisposing to risk of hypoglycaemia, especially in patients treated with insulin [8].”
BackgroundBrown, J. B., Reichert, S. M., Valliere, Y., Webster-Bogaert, S., Ratzki‐Leewing, A. A., Ryan, B. L., & Harris, S. B. (2019) · Diabetes Spectrum · doi:10.2337/ds18-0074 · Cited by 38
Vlckova, V., Cornelius, V. R., Kasliwal, R., Wilton, L., & Shakir, S. (2009) · Drug Safety · doi:10.2165/00002018-200932050-00004 · Cited by 36
Metadata
- Authors
- Cryer, P.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Cryer, P.
- Venue
- Diabetologia
- Published
- 2002-06
- Volume
- 45
- Issue
- 7
- Pages
- 937-948
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2124282046
- Semantic Scholar
- ebdcc733bdd208ee1005932d38511abefb8034d6
- Cited by
- 794
- References
- 58
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 11 · 2023: 15 · 2022: 16 · 2021: 22 · 2020: 18 · 2019: 24 · 2018: 39 · 2017: 49 · 2016: 32 · 2015: 60 · 2014: 65 · 2013: 66 · 2012: 53
- FWCI
- 12.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p60dk020579-35)
- National Institute of Diabetes and Digestive and Kidney Diseases (R37DK027085, P60-DK20579, R37-DK27085, T32 DK07120, T32DK007120)
- National Center for Research Resources (M01-RR00036, M01RR000036)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Patient Safety and Medication Errors
- Keywords
- hypoglycemia, hypoglycemia unawareness, glucose counterregulation, insulin excess, epinephrine response, glucagon response, type 1 diabetes, type 2 diabetes, glycemic control
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Epinephrine, Glucagon, Humans, Hypoglycemia, Insulin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.